Shows
TechNation Radio PodcastEpisode 23-31 A 1-2-3 Punch for Alzheimer’sOn this week’s Tech Nation, Moira speaks with Gene Kinney, the President and CEO of Prothena Biosciences, about a 1-2-3 punch for Alzheimer’s - fighting amyloids, fighting tau, and their work on a vaccine that just might prevent Alzheimer’s altogether. Then Daniel Pink talks about Regret. Research shows you can begin to ease the pain by writing 15 minutes a day for 3 days. His book is “The Power of Regret: How Looking Backward Moves Us Forward”.2023-08-0359 min
BioTech Nation ... with Dr. Moira Gunn23-01 Gene Kinney, President & CEO, Prothena BiosciencesProthena's 1-2-3 punch for Alzheimer’s + their work in Parkinson’s, ALS, and the role of Amyloids in Down Syndrome2023-01-0730 minTechNation Radio PodcastEpisode 22-50 A 1-2-3 Punch for Alzheimer’sOn this week’s Tech Nation, Moira speaks with Gene Kinney, the President and CEO of Prothena Biosciences, about a 1-2-3 punch for Alzheimer’s - fighting amyloids, fighting tau, and their work on a vaccine that just might prevent Alzheimer’s altogether. Then Daniel Pink talks about Regret. Research shows you can begin to ease the pain by writing 15 minutes a day for 3 days. His book is “The Power of Regret: How Looking Backward Moves Us Forward”.2022-12-0759 min
The Pharma Letter PodcastA vaccine for Alzheimer's?With the approval of Aduhelm (aducanumab), the first new Alzheimer’s treatment in decades, people affected by dementia were given new hope that a breakthrough had finally arrived.A year later, the product is yet to gain traction in the USA, the only country to have approved it, and developers Biogen (Nasdaq: BIIB) and Eisai (TYO: 4523) have been forced to rely on confirmatory trials to open up reimbursement - results from which are not expected for some time.Despite the setbacks, the US Food and Drug Administration's accelerated approval for the amyloid beta-targeting antibody has re...2022-06-0640 min
Mad Money w/ Jim CramerDenbury CEO, Off The Charts: Bonds & Prothena CEOThe Dow closed up 31 points and Jim Cramer is breaking down all the action that impacted today's tape. Then, as the landscape of energy changes, Cramer's taking a closer look at carbon capture company Denbury with CEO Chris Kendall to see how they're working towards a carbon neutral future. Next, what are bonds telling investors about where the market's headed? Cramer's going Off The Charts to see what the numbers might be signaling. Plus, Prothena CEO Gene Kinney.2021-08-2544 minTechNation Radio PodcastEpisode 21-14 Sir Edmund HillaryOn this week’s Tech Nation, spurred by the re-opening of expeditions to the summit of Mount Everest, after a one-year closure due to COVID-19, a 1993 interview with Sir Edmund Hillary, who with his climbing partner, Sherpa Tenzing Norgay, was the first to reach the summit. Then Dr. Gene Kinney, the President & CEO of Prothena Biosciences, a new drug in clinical trials for Parkinson’s. How Parkinson’s unfolds in the brain, the idea behind how this drug, and the hope of slowing, if not stopping, disease progress.2021-03-3159 min
TechNation Radio PodcastEpisode 411: Episode 21-14 Sir Edmund HillaryOn this week’s Tech Nation, spurred by the re-opening of expeditions to the summit of Mount Everest, after a one-year closure due to COVID-19, a 1993 interview with Sir Edmund Hillary, who with his climbing partner, Sherpa Tenzing Norgay, was the first to reach the summit. Then Dr. Gene Kinney, the President & CEO of Prothena Biosciences, a new drug in clinical trials for Parkinson’s. How Parkinson’s unfolds in the brain, the idea behind how this drug, and the hope of slowing, if not stopping, disease progress. This is a public episode. If you would like to discus...2021-03-3159 min
The Bio ReportWill a Focus on Protein Dysregulation Help Prothena Break from the FoldThe complexity of neurodegenerative diseases has made it a challenging area for drug developers. Gene Kinney, CEO of Prothena, has long been involved in the pursuit of therapies for diseases such as Alzheimer’s and believes there has been great progress in understanding and targeting these conditions. In fact, he says we are entering a golden age of neuroscience. We spoke to Kinney about the state of drug development for neurodegenerative conditions, Prothena’s pipeline, and its effort to target protein dysregulation in these diseases.2020-09-0335 min